New drug HXN6005 tested in healthy volunteers for first time

NCT ID NCT07449741

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests the safety and tolerability of a single dose of HXN6005 in 32 healthy adults aged 18 to 55. Participants receive either the drug or a placebo and are monitored for side effects and how the drug moves through the body. The study is still recruiting and does not aim to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HXN6005

What could go wrong

This is an early Phase 1 study in healthy volunteers, so it cannot show any treatment benefit. The drug may prove unsafe or ineffective in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Veritus Research

    RECRUITING

    Bayswater, Victoria, 3153, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••